Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $40 to $43.
October 23, 2023 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst has maintained an Outperform rating on Revolution Medicines and raised the price target from $40 to $43.
The news is directly related to Revolution Medicines. The maintained Outperform rating and increased price target by Oppenheimer analyst could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100